CDSCO Told to Close Gaps That Let Narcotic Medicines Leak Into Drug Markets, as Hospitals Face National Quality Grading

The news

New Delhi. The Central Drugs Standard Control Organisation (CDSCO), the national drug regulator, is reviewing its framework to stop the illegal diversion of pharmaceutical drugs containing narcotic drugs and psychotropic substances (NDPS), The Economic Times reports. ‘Diversion’ means medicines made legally — codeine-based cough syrups or certain painkillers and sedatives, for example — leaking out of the licensed supply chain and being sold for addiction rather than treatment. The move follows the 10th apex-level meeting of the National Committee for Coordination on Drug Trafficking (NCORD), held in June under the chairmanship of Union Home Minister Amit Shah, where CDSCO was tasked with addressing regulatory gaps to control illegal diversion by March 2027. This continues the theme of the September 23 card on Mr. Shah’s December 31, 2029 deadline to uproot the drug trade; what is new today is the drug regulator’s specific assignment. A vision document on drug control for 2026–2029, seen by ET, sets defined responsibilities, timelines, targets and monitoring mechanisms; one of CDSCO’s specific targets is to “address regulatory gaps to control illegal pharma diversion” by March next year. The Drugs Consultative Committee (DCC) will examine whether gaps in the framework or its implementation contribute to diversion and recommend measures, which CDSCO is expected to use for an action plan. At the NCORD meeting, Mr. Shah highlighted organised criminal networks’ growing use of encrypted communication, darknet platforms, cryptocurrencies, synthetic drugs and drones. He said seizure-centric policing alone would not be adequate and called for a tech-driven, intelligence-led strategy covering supply reduction, demand reduction, treatment, rehabilitation and capacity building. In a separate report, ET says the government is firming up a national quality framework to grade public and private hospitals on quality and safety, aligned with international standards. The idea has gained momentum under the new team at NITI Aayog, which last week held a stakeholder consultation under member M Srinivas on a “credible, sustainable and patient-centric framework”. Parameters under discussion include patient-reported outcome and experience measures, readmission rates and medication errors, with sub-indicators such as post-transplant survival and postoperative mortality after cancer surgery. An official said the framework should be ready by year-end and grading could begin next financial year. The paper notes that private hospitals follow the National Accreditation Board for Hospitals & Healthcare Providers (NABH) framework, but its reports and outcomes are not publicly disclosed, whereas the UK’s National Health Service reports and audits outcomes. The government also expects grading to boost medical tourism. The syllabus link is GS2 (health, government policies) and GS3 (internal security, drug trafficking).

Static syllabus linkage

1. The Drugs and Cosmetics Act splits drug regulation between the Centre and the States. The Drugs and Cosmetics Act, 1940, and its Rules of 1945 regulate the import, manufacture, distribution and sale of drugs in India. CDSCO, headed by the Drugs Controller General of India (DCGI) under the Ministry of Health and Family Welfare, approves new drugs and clinical trials, regulates imports and sets standards. State drug controllers license the manufacture and sale of most drugs, including every chemist shop, and carry out most inspections. The Act creates two advisory bodies: the Drugs Technical Advisory Board on technical matters and the Drugs Consultative Committee, made up of Central and State representatives, to secure uniformity in the Act’s administration across the country.
2. The Schedules of the Drugs Rules govern how risky medicines are sold. Schedule H of the Drugs Rules lists prescription-only drugs that a chemist may sell only against a registered medical practitioner’s prescription. Schedule H1 was added for certain antibiotics, anti-tuberculosis drugs and habit-forming drugs, and requires chemists to keep a separate register of the prescriber, patient, drug and quantity. Schedule X covers narcotic and psychotropic drugs with the strictest record-keeping and storage conditions. Diversion usually happens where these record-keeping duties are weakly enforced, since the State inspectorate is thin compared with the number of retail outlets.
3. The NDPS Act and the NCB form the enforcement side. The Narcotic Drugs and Psychotropic Substances Act, 1985, prohibits the production, possession, sale and transport of narcotic drugs and psychotropic substances except for medical and scientific purposes, and imposes graded punishments based on small, intermediate and commercial quantities. The Narcotics Control Bureau, constituted in 1986 under the Act, is the nodal central agency for coordinating drug-law enforcement and functions under the Ministry of Home Affairs. The Act gives effect to India’s obligations under the UN Single Convention on Narcotic Drugs, 1961, the Convention on Psychotropic Substances, 1971, and the UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. Article 47 of the Constitution directs the State to endeavour to prohibit the consumption, except for medicinal purposes, of drugs injurious to health.
4. Hospital quality in India rests on voluntary accreditation and State-level regulation. Health, including hospitals and dispensaries, is a State subject under Entry 6 of the State List. The Clinical Establishments (Registration and Regulation) Act, 2010, provides for registration and minimum standards of clinical establishments, but applies only in States and Union Territories that have adopted it. NABH is a constituent board of the Quality Council of India that accredits hospitals against quality and patient-safety standards; accreditation is voluntary, though government insurance schemes use it for empanelment and higher reimbursement. For public facilities, the Health Ministry runs the National Quality Assurance Standards (NQAS), with certification of district hospitals and health centres. None of these systems publishes comparable clinical outcomes, such as surgical mortality, for each hospital.

Why UPSC loves this

1. GS2 and GS3 both claim the drug problem. Mains has asked about drug abuse among youth, the drug trade as a threat to internal security, and the link between narcotics, terror financing and porous borders, particularly in Punjab and the Northeast. Pharmaceutical diversion is the less-discussed side of the problem, and a candidate who can explain how legal medicines feed addiction will stand out from answers that only discuss the Golden Crescent and Golden Triangle.
2. Prelims tests the regulatory map. UPSC has asked about the functions of CDSCO, the NDPS Act, the Narcotics Control Bureau and the international drug conventions. The DTAB and DCC under the Drugs and Cosmetics Act, the Schedules H, H1 and X, and the voluntary character of NABH accreditation under the Quality Council of India are high-probability facts.
3. Health-system quality is a recurring governance theme. Questions on the regulation of private hospitals, medical tourism and patient rights have appeared in GS2 and the Essay paper. The hospital-grading plan offers a live example of using transparency rather than inspection as a regulatory tool, and of NITI Aayog’s role in shaping health policy.

Analysis

1. Pharma diversion is a regulatory failure before it is a policing problem. A codeine cough syrup or a controlled sedative that reaches an addict passed through a licensed manufacturer, a licensed distributor and a licensed chemist first. That is why the NCORD assignment goes to the drug regulator, not only to the police. The gap lies in the split system: the Centre approves the product, but States license the thousands of outlets that sell it, and their inspectorates are small. Asking the DCC — which exists precisely to bring the Centre and States together — to find the gaps is therefore the right forum. Its weakness is that it is advisory, so the real test will be whether States accept binding measures.
2. Track-and-trace is the obvious answer, but it has costs. The most effective tool against diversion is a digital record that follows each pack of a controlled medicine from factory to patient, flagging unusual volumes at any point. The September 24 card on the NHRC’s recommendation of QR-code track-and-trace for spurious medicines points the same way. Such systems impose costs on small manufacturers and chemists and risk making legitimate pain relief harder to obtain for patients who need it, such as cancer patients needing opioids, already a problem in India. A good design should target a narrow list of high-risk products rather than burden the whole trade.
3. Moving beyond seizure-centric policing is correct, but demand is where the money is short. Mr. Shah’s emphasis on intelligence-led action against networks using darknet platforms, cryptocurrency and drones recognises that seizures measure activity, not success. Yet the vision document’s demand-reduction side — treatment, rehabilitation and prevention among youth — is where India has historically underinvested, and the ET report gives no figures on it. Without enough de-addiction capacity, a crackdown on supply can push users towards more dangerous synthetic drugs. A balanced strategy would treat the addicted person as a patient, reserving criminal enforcement for traffickers.
4. Hospital grading will work only if outcomes are published and audited independently. The ET report is right that NABH accreditation certifies processes but does not tell patients how often a hospital’s patients die after cancer surgery or survive a transplant. The paper says private hospitals ‘must comply’ with NABH; in fact accreditation is voluntary, which is part of the problem, since a hospital can simply stay out. Outcome indicators are also easy to game: hospitals can refuse high-risk patients to protect mortality figures unless the data is risk-adjusted for the severity of cases. A credible system needs independent audits, as the UK has, and clear legal backing, which the Clinical Establishments Act, adopted only in some States, cannot yet provide.
5. Medical tourism should not be the main reason to grade hospitals. The government expects grading to boost medical tourism, and foreign patients do look for internationally benchmarked quality. But if grading becomes a marketing exercise for a few corporate hospitals, it will do little for the district hospital patient. Including public hospitals, as the official suggests, is the more important part. Grades can guide Ayushman Bharat–PM-JAY empanelment and payment, rewarding quality with money. The counter-risk is that underfunded public hospitals receive low grades that demoralise staff without bringing resources, so grading must be tied to support, not only to ranking.

Administrator's brainstorm